{"id":"azd6738-and-olaparib","safety":{"commonSideEffects":[{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Vomiting"},{"rate":"40%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL521686","moleculeType":"Small molecule","molecularWeight":"434.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD6738 and olaparib are PARP inhibitors that work by blocking the action of poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. By inhibiting PARP, these drugs can induce DNA damage and trigger cell death in cancer cells.","oneSentence":"PARP inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:21.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT03787680","phase":"PHASE2","title":"Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-10-31","conditions":"Prostate Cancer","enrollment":49},{"nctId":"NCT03462342","phase":"PHASE2","title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-03-09","conditions":"High Grade Serous Carcinoma","enrollment":123},{"nctId":"NCT04090567","phase":"PHASE2","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-28","conditions":"Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":60},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT04417062","phase":"PHASE2","title":"Olaparib With Ceralasertib in Recurrent Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-24","conditions":"Osteosarcoma, Osteosarcoma Recurrent","enrollment":63},{"nctId":"NCT04065269","phase":"PHASE2","title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-11-27","conditions":"Gynaecological Cancers","enrollment":174},{"nctId":"NCT03579316","phase":"PHASE2","title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-07","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":96},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT03878095","phase":"PHASE2","title":"Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-30","conditions":"Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm","enrollment":24},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT03740893","phase":"PHASE2","title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-10-15","conditions":"Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD","enrollment":119},{"nctId":"NCT03682289","phase":"PHASE2","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2019-01-17","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm","enrollment":89},{"nctId":"NCT02937818","phase":"PHASE2","title":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-28","conditions":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","enrollment":72},{"nctId":"NCT04298021","phase":"PHASE2","title":"DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-06-25","conditions":"Bile Duct Cancer, Chemotherapy Effect","enrollment":74},{"nctId":"NCT02576444","phase":"PHASE2","title":"OLAParib COmbinations","status":"TERMINATED","sponsor":"Joseph Paul Eder","startDate":"2015-11","conditions":"Cancer","enrollment":67},{"nctId":"NCT03022409","phase":"PHASE1","title":"A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-18","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT04239014","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-08-07","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03428607","phase":"PHASE2","title":"Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2018-10-17","conditions":"SCLC","enrollment":26},{"nctId":"NCT03182634","phase":"PHASE2","title":"The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2016-12-15","conditions":"Advanced Breast Cancer","enrollment":1150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD6738 and olaparib","genericName":"AZD6738 and olaparib","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PARP inhibitor Used for Ovarian cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}